Sales Force Effectiveness USA 2010

eyeforpharma17-18 May 2010, Princeton, NJ, USA.
SFE USA is a premier conference for pharma. Learn how to develop a winning sales strategy from pharma leaders. 10 Industry VPs will deliver sessions on healthcare reform, customer-centric models, and CRM tools.

SFE USA Program

Pharma In 2010 And Beyond

  • Lean, Mean, Switching machines- What is the future of Sales Force Effectiveness?
    Tony Fross, Senior Director WBB Business Excellence Group, Pfizer
  • Mergers & Acquisitions: What does the future hold?
    Richard Skelly, Senior Director Commercial Evaluations, AstraZeneca
  • Emerging Markets: Building BRIC(s) and Blocs
    Charlotte Sibley, Senior Vice President CBS Business Management, Shire
  • The future of pharma rests on the impending Health Care bill – be prepared and understand the implications
    Pharma Vice President confirmed, Genentech

Sales Excellence

  • Achieve more with less: Which commercial model will be most successful for your company?
    Barry Duke, Vice President Sales, Genzyme
  • Insights into Taro's commercial model strategies
    Joe Malta, Vice President Sales & Marketing, Taro Pharmaceuticals
  • The optimal size of your workforce: How small is big enough?
    Tracy Mills, Senior Director Sales Force Effectiveness, Endo Pharmaceuticals
  • Target managed markets and bring value to these powerful stakeholders
    Don Sawyer, Vice President Commercial Operations, AstraZeneca
  • How to ensure a long-term relationship with your key accounts
    Tony Zecca, Senior Director Sales Strategy, Effectiveness & Innovation, AstraZeneca

Sales Tools And Technology

  • Multi-Channel Management: Integrating promotion effectively across all channels
    Paulash Mohsen, VP Multichannel Marketing, Pfizer
  • Capitalise on the potential of e-detailing to reduce your marketing costs
    John Rotondo, VP & General Manager Commercial Operations, Bayer
  • Case Study: Closed Loop Marketing In A multi-channel environment
    Marc Valdiviezo, Director Marketing Excellence, Sanofi-Aventis
  • What technology should you provide your sales force to achieve optimum sales effectiveness?
    Edson Gemo, Senior Director Business Technology Sales Force Effectiveness Solution Center, Pfizer
    Steve Winawer, Senior Director, US Business Technology, Commercial Operations, Patient & Physician Marketing, Pfizer

Training And Development

  • The Evolution of Physician Behaviour and Implications for New Physician Access Models
    Mark Gleason, Senior Vice President, Corporate Development, Aptilon
  • SUPER PANEL: Scientist Vs salesman: Which approach will enable your sales reps to raise their value to the industry?
    Tim Ryan, Executive Director, Boehringer Ingelheim
    Christine Barczak, East Area Vice Presidnet, GSK
    Todd Lambert, Vice President Sales, Shire,
    Don Hribek, Senior Director of Strategic Accounts, EMD Serono
    Moderator: Greg Neal, Managing Partner, Rx Business Advantage Consulting
  • A sales force to be reckoned with: Transforming Sales Forces with talent upgrades, skills training, and business processes
    Joe Coffey, Vice President Sales, Baxter
  • Case Study: Discover the methodology behind successful training delivery
    Mike Capaldi, AVP Sales Training & Leadership Development, Sanofi-Aventis
  • Value Creation- The Next Frontier for Pharma
    Angela Bakker Lee, Principal, ZS Associates

For further information and registration, please visit:
http://www.eyeforpharma.com/sfeusa

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

In mice, stem cells seem to work in fighting obesi…

Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for ...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Research shows how a moderate dose of alcohol prot…

For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A stu...

'Kiss of death' cancer

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negativ...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...